Evidence map›Paper›PMID 33058892›Full record

ArticleJournal of pharmaceutical sciences2021

Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR

Jacqueline Bezençon, Chitra Saran, Janine Hussner, James J Beaudoin, Yueping Zhang, Hong Shen, John K Fallon, Philip C Smith, Henriette E Meyer Zu Schwabedissen, Kim L R Brouwer

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jacqueline BezençonDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Chitra SaranDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; Department of Pharmacology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Janine HussnerBiopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
James J BeaudoinDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Yueping ZhangDepartment of Metabolism and Pharmacokinetics, Bristol Myers Squibb Company, Princeton, NJ, USA.
Hong ShenDepartment of Metabolism and Pharmacokinetics, Bristol Myers Squibb Company, Princeton, NJ, USA.
John K FallonDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Philip C SmithDivision of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Henriette E Meyer Zu SchwabedissenBiopharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Kim L R BrouwerDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Electronic address: kbrouwer@unc.edu.
University of North Carolina at Chapel Hill · USBristol-Myers Squibb (United States) · USUniversity of Basel · CH

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
Mechanisms of Altered Hepatic Transport: Impact on Drug TherapyR35GM122576 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER · 2017 to 2026
$5.7M
Shared UPLC-MS/MS for Absolute Quantitative ProteomicsS10RR024595 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SMITH, PHILIP C · 2008 to 2008
$381k
Elucidating the Role of Organic Solute Transporter (OST) Alpha/Beta in Bile Acid Transport and Drug InteractionsF31DK120196 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BEAUDOIN, JAMES JOHN · 2019 to 2020
$51k
NCRR NIH HHS S10 RR024595NIDDK NIH HHS F31 DK120196NIEHS NIH HHS P30 ES010126NIGMS NIH HHS R35 GM122576
6 · The paper itself

Abstract

Recent studies have focused on coproporphyrin (CP)-I and CP-III (CPs) as endogenous biomarkers for organic anion transporting polypeptides (OATPs). Previous data showed that CPs are also substrates of multidrug resistance-associated protein (MRP/Mrp) 2 and 3. This study was designed to examine the impact of loss of Mrp2 function on the routes of excretion of endogenous CPs in wild-type (WT) Wistar compared to Mrp2-deficient TR

Indexed as

CoproporphyrinsProteomicsAnimalsATP-Binding Cassette, Sub-Family C ProteinsChromatography, LiquidHeLa CellsHumansLiverMultidrug Resistance-Associated Protein 2RatsRats, WistarTandem Mass SpectrometryABCC2 protein, humanATP-Binding Cassette, Sub-Family C Proteinscoproporphyrin ICoproporphyrinsMultidrug Resistance-Associated Protein 2Biomarker(s)Disease effect(s)Membrane transportMultidrug resistance-associated protein(s) (MRP)Organic anion transporting polypeptide(s) (OATP)ProteomicTransporter(s)

Identifiers

PMID33058892
PMCPMC7767637
OpenAlexW3093004860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.